Correspondence 0001628280-23-002537 from Mineralys Therapeutics, Inc. (MLYS) (CIK 0001933414) (MLYS)
Mineralys Therapeutics, Inc. (MLYS) (CIK 0001933414)
Date: Feb. 7, 2023 · CIK: 0001933414 · Accession: 0001628280-23-002537
AI Filing Summary & Sentiment
File numbers found in text: 333-269282
Letter
Document
Mineralys Therapeutics, Inc.
150 N. Radnor Chester Road, Suite F200
Radnor, PA 19087
February 7, 2023
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Re: Mineralys Therapeutics, Inc.
Registration Statement on Form S-1, as amended
File No. 333-269282
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Mineralys Therapeutics, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on February 9, 2023, or as soon as practicable thereafter.
Please contact Matthew T. Bush of Latham & Watkins LLP, counsel to the Company, at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
Very truly yours,
MINERALYS THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm Document Mineralys Therapeutics, Inc. 150 N. Radnor Chester Road, Suite F200 Radnor, PA 19087 February 7, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Mineralys Therapeutics, Inc. Registration Statement on Form S-1, as amended File No. 333-269282 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Mineralys Therapeutics, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on February 9, 2023, or as soon as practicable thereafter. Please contact Matthew T. Bush of Latham & Watkins LLP, counsel to the Company, at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter. Very truly yours, MINERALYS THERAPEUTICS, INC. By: /s/ Jon Congleton Jon Congleton Chief Executive Officer cc: Adam Levy, Mineralys Therapeutics, Inc. Cheston J. Larson, Latham & Watkins LLP Matthew T. Bush, Latham & Watkins LLP Ilir Mujalovic, Shearman & Sterling LLP